Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12931062 | 0.87 | ADORA1 (0.53) | ADORA1GLAGPR119MEN1KMT2A | |
| SCHEMBL6218755 | 0.86 | ADORA1 (0.49) | ADORA1GLAGPR119MEN1KMT2A | |
| SCHEMBL31195159 | 0.85 | ADORA1 (0.48) | ADORA1GLAGPR119MEN1KMT2A | |
| SCHEMBL6541860 | 0.84 | ADORA1 (0.47) | ADORA1GLAGPR119MEN1KMT2A | |
| SCHEMBL19462690 | 0.80 | ADORA1 (0.43) | ADORA1GPR119MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL29234093 | 0.79 | ADORA1 (0.42) | ADORA1GPR119MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3615685 | 0.78 | L3MBTL1 (0.44) | ADORA1GLAGPR119SMN1; SMN2ALDH1A1 | |
| SCHEMBL630338 | 0.78 | ADORA1 (0.49) | ADORA1GLAGPR119MEN1KMT2A | |
| SCHEMBL25341230 | 0.78 | ESR2 (0.42) | ADORA1GPR119MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4111304 | 0.77 | KMT2A (0.49) | MEN1KMT2ASMN1; SMN2ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119930866-A | Catalyst component containing pyrroline compound, preparation method thereof, olefin polymerization catalyst, olefin polymerization method and olefin polymer | 中国石油化工股份有限公司 | 2025-05-06 | — | — | CN | claimed |
| CN-119930866-A | Catalyst component containing pyrroline compound, preparation method thereof, olefin polymerization catalyst, olefin polymerization method and olefin polymer | 中国石油化工股份有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-117561058-A | CDK2 inhibitors and methods of use thereof | 塞迪拉治疗股份有限公司 | 2024-02-13 | — | — | CN | disclosed |
| US-20230121337-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| WO-2022272106-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| US-10266489-B2 | Pyrrolic amide compound and preparation method and application thereof | HITGEN LTD (CN) | 2019-04-23 | — | — | US | disclosed |
| US-10266489-B2 | Pyrrolic amide compound and preparation method and application thereof | HITGEN LTD (CN) | 2019-04-23 | — | — | US | disclosed |
| EP-3241823-B1 | PYRROLE AMIDE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | HITGEN LTD (CN) | 2019-04-17 | — | — | EP | disclosed |
| EP-3241823-B1 | PYRROLE AMIDE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | HITGEN LTD (CN) | 2019-04-17 | — | — | EP | disclosed |
| EP-3241823-A1 | PYRROLE AMIDE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | Hitgen Ltd. (CN) | 2017-11-08 | — | — | EP | disclosed |
| US-20070154882-A1 | Beta-polypeptides that inhibit cytomegalovirus infection | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-07-05 | — | — | US | disclosed |
| US-20070123709-A1 | Beta-amino acids | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-05-31 | — | — | US | disclosed |
| EP-0865445-B1 | 3-AMINOETHYL-N-AMIDINO-2,5-DIHYDROPYRROLE DERIVATIVES HAVING ARGININE MIMETIC PROPERTIES | AKZO NOBEL NV (NL) | 2003-04-02 | — | — | EP | disclosed |
| US-6429288-B1 | OSTEOPOROSIS, OSTEOARTHRITIS, AND RHEUMATIC DISEASES | ROCHE DIAGNOSTICS GMBH (DE) | 2002-08-06 | — | — | US | disclosed |
| US-20020026034-A1 | 3-AMINOETHYL-N-AMIDINO-2,5-DIHYDROPYRROLE DERIVATIVES HAVING ARGININE MIMETIC PROPERTIES | BOEHRINGER MANNHEIM GMBH (DE) | 2002-02-28 | — | — | US | disclosed |
| CN-1269806-A | Piptides containing arginine mimetic for treatment of bone metabolic disorders, their production and drugs containing these compounds | ROCHE DIAGNOSTICS GMBH (DE) | 2000-10-11 | — | — | CN | disclosed |
| EP-1009770-A1 | PEPTIDES CONTAINING AN ARGININE MIMETIC FOR THE TREATMENT OF BONE METABOLIC DISORDERS, THEIR PRODUCTION, AND DRUGS CONTAINING THESE COMPOUNDS | Roche Diagnostics GmbH (DE) | 2000-06-21 | — | — | EP | disclosed |
| WO-1999012970-A1 | PEPTIDES CONTAINING AN ARGININE MIMETIC FOR THE TREATMENT OF BONE METABOLIC DISORDERS, THEIR PRODUCTION, AND DRUGS CONTAINING THESE COMPOUNDS | ROCHE DIAGNOSTICS GMBH (DE) | 1999-03-18 | — | — | WO | disclosed |
| EP-0902036-A1 | Peptide containing an arginine mimetic for the treatment of osteoporosis, their production, and drugs containing these compounds | Roche Diagnostics GmbH (DE) | 1999-03-17 | — | — | EP | disclosed |
| US-5856309-A | TREATING OSTEOPOROSIS, INFLAMMATION OR A DISEASE WHICH IS DUE TO A THROMBOEMBOLIC EVENT | BOEHRINGER MANNHEIM GMBH (DE) | 1999-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020026034-A1 | 3-AMINOETHYL-N-AMIDINO-2,5-DIHYDROPYRROLE DERIVATIVES HAVING ARGININE MIMETIC PROPERTIES | ARG1, ODC1, ARG2 | ADORA1 1178/4885GLA 4022/4885GPR119 353/4885 |
| US-20070123709-A1 | Beta-amino acids | BCAT1, MARCKS, YWHAZ | ADORA1 4519/4885GLA 888/4885GPR119 3554/4885 |
| US-20230121337-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK20, CDK2AP2 | ADORA1 4674/4885GLA 2083/4885GPR119 3965/4885 |
| US-10266489-B2 | Pyrrolic amide compound and preparation method and application thereof | HDAC1, HDAC3, HDAC11 | ADORA1 3068/4885GLA 405/4885GPR119 2498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.